Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Apogee Therapeutics, Inc.NASDAQ: APGE
Accumulated OCI · Q2 FY2026 · quarter ended Jun 2026
Accumulated OCI turns negative
Q2 FY2026 Accumulated OCI was -$2.5M, compared with $685K a year earlier. Over 3 fiscal years it compounded at -20.4% a year.
Context
- Accumulated OCI amounted to 0.2% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Accumulated OCI increased in 2 of the last 3 fiscal years.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -465.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 1.08M USD
- Year-over-year change
- +18.0%
- 3-year CAGR
- -20.4%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.08M | +18.0% |
| FY2024 | 2024-12-31 | 915K | +178.1% |
| FY2023 | 2023-12-31 | 329K | -84.6% |
| FY2022 | 2022-12-31 | 2.14M | — |
Accumulated OCI vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -465.4% is the 6th highest of 8, against a peer median of -32.1%.
- Accumulated OCI amounts to 0.2% of total assets for APGE, versus a peer median of 0.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | Dec 2025 | CN¥1.33B CNY | +360.1% | — | 33.5% |
| Sep 2026 | $122.6M USD | +5.8% | +102.7% | 7.3% | |
| Mar 2026 | $10M USD | +3032.6% | — | 0.8% | |
| Mar 2026 | $1.41M USD | -32.1% | — | 0.2% | |
| Jun 2026 | $214K USD | -99.5% | +5.0% | 0.0% | |
| Sep 2026 | $0 USD | — | — | 0.0% | |
| Jun 2026 | $0 USD | — | — | 0.0% | |
| Jun 2026 | -$2.5M USD | -465.4% | -20.4% | 0.2% | |
IRONDisc Medicine, Inc. | Sep 2026 | -$2.77M USD | -485.8% | — | 0.4% |
| Sep 2026 | -$5.05M USD | -1159.3% | — | 0.4% | |
| Peer median (excluding APGE) | — | -32.1% | +53.8% | 0.4% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.